STING激活增强靶向T细胞的免疫治疗对急性髓系白血病的疗效
本研究探讨STING激动剂cGAMP或diABZI能否增强CD33双特异性T细胞衔接分子AMG 330对急性髓系白血病(AML)的杀伤作用。体外细胞毒性实验、免疫印迹、转录组分析及CRISPR-Cas9敲除实验显示,STING激活可大幅增强AMG 330介导的AML细胞毒性,并在原代AML细胞和异种移植AML模型中得到验证。机制上,活化的T细胞通过效应细胞因子IFN-γ和肿瘤坏死因子使AML细胞对STING激活更敏感,形成正反馈环路增强杀伤。
要点
- STING激动剂cGAMP或diABZI可大幅增强AMG 330对AML细胞的体外细胞毒性。
- 原代AML细胞和异种移植AML模型验证了STING激活增强AMG 330杀伤的效应。
- IFN-γ在AMG 330介导的AML细胞毒性和AML细胞对STING激动剂响应中起关键作用。
核心结论
- STING激活可增强CD33双特异性T细胞衔接分子AMG 330对AML的杀伤,作者提出将CD33靶向双特异性抗体与STING激动剂联合以改善疗效。
研究设计与样本
- 研究采用体外细胞毒性实验、免疫印迹、转录组分析和广泛的CRISPR-Cas9敲除实验,并在原代AML细胞和异种移植AML模型中验证。
主要发现
- AMG 330联合STING激动剂cGAMP或diABZI时,对AML的细胞毒性可大幅增强。
- STING激活对AML细胞有直接细胞毒性作用,活化的T细胞通过效应细胞因子IFN-γ和肿瘤坏死因子使AML细胞对STING激活更敏感,导致I型IFN产生增加和干扰素刺激基因诱导。
- 该过程反馈至T细胞,进一步增加效应细胞因子并形成整体细胞毒性T细胞表型,贡献cGAMP/diABZI增强AMG 330介导裂解的有益效应。
- IFN-γ在AMG 330介导的AML细胞毒性及使AML细胞对STING激动剂响应中起关键作用。
临床怎么用
- 作者提出通过将CD33靶向双特异性抗体与STING激动剂联合来改善其疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell-recruiting bispecific antibodies (BsAbs) are in clinical development for relapsed/refractory acute myeloid leukemia (AML). Despite promising results, early clinical trials have failed to demonstrate durable responses. We investigated whether activation of the innate immune system through stimulator of interferon (IFN) genes (STING) can enhance target cell killing by a BsAb targeting CD33 (CD33 bispecific T-cell engager molecule; AMG 330). Indeed, we show that cytotoxicity against AML mediated by AMG 330 can be greatly enhanced when combined with the STING agonist 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) or diamidobenzimidazole (diABZI). We used in vitro cytotoxicity assays, immunoblotting, transcriptomic analyses, and extensive CRISPR-Cas9 knockout experiments to investigate the enhancing effect of a STING agonist on the cytotoxicity of AMG 330 against AML. Importantly, we validated our findings with primary AML cells and in a xenograft AML model. Mechanistically, in addition to direct cytotoxic effects of STING activation on AML cells, activated T cells render AML cells more susceptible to STING activation through their effector cytokines, IFN-γ and tumor necrosis factor, resulting in enhanced type I IFN production and induction of IFN-stimulated genes. This feeds back to the T cells, leading to a further increase in effector cytokines and an overall cytotoxic T-cell phenotype, contributing to the beneficial effect of cGAMP/diABZI in enhancing AMG 330-mediated lysis. We established a key role for IFN-γ in AMG 330-mediated cytotoxicity against AML cells and in rendering AML cells responsive to STING agonism. Here, we propose to improve the efficacy of CD33-targeting BsAbs by combining them with a STING agonist.
引用
- Linder A, Nixdorf D, Kuhl N, et al. STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. Blood. 2025. PMID: 40009483. doi:10.1182/blood.2024026934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。